Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia

Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia Opinion EDITORIAL Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia David W. Volk, MD, PhD; David A. Lewis, MD Changes in state laws that have made cannabis more avail- the study (schizophrenia, schizoaffective disorder, and first- episode psychosis) or are similarly altered in other psychiatric able for medical indications or recreational use have raised concerns about potential unintended negative societal con- or neurologic disorders that can be accompanied by psychosis. sequences of cannabis use. For example, epidemiologic studies Second, as the authors acknowledge, elevated anandamide have reported associations levels have been associated with other factors such as inflam- between cannabis use and mation, and cortical immune activation has previously been Related article page 914 schizophrenia, including reported in schizophrenia (reviewed in Volk ). Finally, their a greater risk of developing the disorder, an earlier age findings of an inverse association between anandamide lev- at onset, more severe symptoms, and more frequent els and symptom severity and the normalization of ananda- hospitalizations. Furthermore, a 2018 large-scale genome- mide levels after successful antipsychotic treatment suggests wide association study reported that genetic risk for schizo- that peripheral serum anandamide levels may be more useful phrenia is also associated with a causal http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia

JAMA Psychiatry , Volume 76 (9) – Sep 5, 2019

Loading next page...
 
/lp/american-medical-association/insights-into-the-pathophysiology-of-endocannabinoid-signaling-in-MoniH0y0BN
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2019.0844
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia David W. Volk, MD, PhD; David A. Lewis, MD Changes in state laws that have made cannabis more avail- the study (schizophrenia, schizoaffective disorder, and first- episode psychosis) or are similarly altered in other psychiatric able for medical indications or recreational use have raised concerns about potential unintended negative societal con- or neurologic disorders that can be accompanied by psychosis. sequences of cannabis use. For example, epidemiologic studies Second, as the authors acknowledge, elevated anandamide have reported associations levels have been associated with other factors such as inflam- between cannabis use and mation, and cortical immune activation has previously been Related article page 914 schizophrenia, including reported in schizophrenia (reviewed in Volk ). Finally, their a greater risk of developing the disorder, an earlier age findings of an inverse association between anandamide lev- at onset, more severe symptoms, and more frequent els and symptom severity and the normalization of ananda- hospitalizations. Furthermore, a 2018 large-scale genome- mide levels after successful antipsychotic treatment suggests wide association study reported that genetic risk for schizo- that peripheral serum anandamide levels may be more useful phrenia is also associated with a causal

Journal

JAMA PsychiatryAmerican Medical Association

Published: Sep 5, 2019

References